Ernest H. Pfadenhauer, MS., Ernest H. Pfadenhauer, was most recently (2010-2012) a founder and the Chief Operations Officer of Epiomed, Inc., a company developing new chemical entity treatments for diseases of the central nervous system. From 2007-2009, he held the position of VP, Pharmaceutical Development at Cenomed BioSciences, LLC, a joint venture between Abraxis Bioscience and Cenomed Inc. In this position he was responsible for new compound chemistry research, discovery and IND enabling ADME and CMC development. Prior to that, he was a consultant to the pharmaceutical industry, assisting principally in the manufacturing and controls area of new drug development, assisting in the successful approval process of several INDs and NDAs. From 1996 to 2002, Ernie was Director, Chemistry Research at NeoTherapeutics, Inc. He was responsible for GMP synthesis and formulation of CNS and oncology drugs, compilation of the Chemistry, Manufacturing and Controls sections of regulatory submissions, management of new drug pharmacokinetics, metabolism, and bioanalytical development, and had primary responsibility for biopharmaceutical areas of drug discovery. From 1987 to 1996, Mr. Pfadenhauer was employed in various positions as a research and project scientist at Baxter Healthcare Corporation, working in the clinical chemistry diagnostic, instrument design, and bioprosthetic heart valve development areas. While at Baxter, he was directly responsible for the design, manufacturing, and post-launch support of several successful commercial products. From 1970 until 1987, Mr. Pfadenhauer was employed at Newport Pharmaceuticals, where he was the Supervisor of Quality Control, and later a Senior Research Scientist. During that period, he was involved in the analytical, pharmacokinetic, and metabolism areas of new drug development. Mr. Pfadenhauer holds a B.S. and M.A. degree in Physical Chemistry from the University of California, Santa Barbara, where he graduated Cum Laude and was awarded the highest honor in the Chemistry Department.